GIGABYTE
14.4.2020 11:02:06 CEST | Business Wire | Press release
The leading personal computer brand, GIGABYTE, recently received the 2020 Red Dot Design Award for two creator laptops from the AERO line – AERO 15 OLED & AERO 17 – as well as two professional gaming laptops – AORUS 15G and AORUS 17X. The recognition further establishes GIGABYTE’s role as a market leader in the laptop industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200414005017/en/
There were over 6,500 entries from 60 countries contending in this year’s Red Dot Design Awards. GIGABYTE is committed to producing the AERO Creator Laptop and AORUS Gaming Laptop lines in Taiwan. With their ultra-slim bezel, Xrite Pantone color calibration, Microsoft Azure AI, and other industry leading technologies, GIGABYTE’s laptops have already been recognised with the European Hardware Awards for Best Notebook as well as receiving Taiwan Excellence Awards. The notebooks are now honored with the 2020 Red Dot Design Award.
AORUS: Redefining Gaming Laptops
AORUS laptops are fast and powerful, with screens that offer a high refresh rate coupled with exceptional mechanical keyboards. In 2020, AORUS takes it further by collaborating with G2 Esports, a professional global esports team, to develop a purpose-built gaming laptop that caters to professional gamer’s needs. The comprehensive and integrative design concept was crucial for GIGABYTE in winning the award.
The product design is infused with a sense of extreme performance, with the flagship AORUS 17X being inspired by super cars and a fighter jet. The chassis is created using CNC (Computer Numerical Control) technology, carving the all-aluminum chassis into a robust frame with defined angles. RGB LED lights are scattered from end to end showcasing the flagship laptop’s overwhelming speed and power.
The second winning laptop, the brand new AORUS 15G, is a professional gaming laptop for on-the-road gamers: though also equipped with a mechanical keyboard, the AORUS 15G is lighter and has a longer lasting battery. The design of AORUS 15G was also inspired by sports cars with the side of the chassis embellished with faux race car features to create a feel of extreme sports while adding a touch of minimalist modernism.
AERO: An Equilibrium of Performance and Mobility
The aesthetic of the creator laptops in the AERO line are inspired by science fiction films. The full aluminum chassis is finished with NIL (Nano-Imprint Lithography), presenting superior quality that is simple but by no means underwhelming. Steven Chen, VP of GIGABYTE’s Mobile Business Center, stated that the beauty of AERO laptops lies in “more possibilities” and therefore they must have lighter bodies, long-lasting batteries, and great performance without any compromise due to overheating.
The AERO line is well-balanced in many aspects, visual artist Rus Khasonov was inspired by AERO to create videos with the AERO 15 OLED, “With AERO, I can render with After Effects and edit with Photoshop at the same time. I’m deeply impressed that such a light body can offer such performance.”
The full line of creator laptops from AERO, including the 15” AERO 15 OLED and 17” AERO 17 HDR with 4K monitors as well as the AERO 15 and AERO 17 with FHD monitors, are available starting on 16th April. The graphics card powerhouse, NVIDIA, is upping the prize for creators and has promised free access to Adobe Creative Cloud for three months to anyone buying the RTX Studio equipped models. For details, please refer to the official website: https://www.gigabyte.com/Laptop
- ENDS -
About GIGABYTE
GIGABYTE is an engineer, visionary, and leader in the world of tech that uses its hardware expertise, patented innovations, and industry leadership to create, inspire and advance. Renowned for over 30 years of award-winning excellence, GIGABYTE is a cornerstone in the HPC community, providing businesses with server and data center expertise to accelerate their success. At the forefront of evolving technology, GIGABYTE is devoted to inventing smart solutions that enable digitalization from edge to cloud, and allow customers to capture, analyze, and transform digital information into economic data that can benefit humanity and "Upgrade Your Life". Please visit https://www.gigabyte.com/ for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom